Avid Bioservices Inc (CDMO)

[entdoc]

dia, agreed. I seriously doubt that the "real" results of Bavi PII NSCLC trials will be materially different than those we've seen, and think all the players have a very good idea of how effective this approach is going to be to prolonging meaningful lifetime to those with the disease. If the side-effect profile is close to what we've been led to believe (and there are a few gaps there too), then the most sensible solution to this conundrum is to allow a PIII trial of Bavi in less seriously ill patients as co-therapy with SOC, including Bavi+Irradiation. Anti-PS is not going away, so it would behoove the DrWests of the world to stay tuned and keep reading about it. The science is compelling because it is so sensible. The company is so valuable because it has the experience with humans.